Crystalline Inorganic Anion Exchanger 188Re Generator

结晶无机阴离子交换器188Re发生器

• 批准号: 6944263
• 负责人: ALAN J CISAR
• 金额: $ 46.3万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-16 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6944263
• 关键词: anions; beta radiation; bioengineering /biomedical engineering; biomedical equipment development; chemical kinetics; chemical stability; chemical structure function; chemical synthesis; crystallization; heavy metals; intermolecular interaction; ion exchange chromatography; tungsten

DESCRIPTION (provided by applicant): A high-energy beta (beta-) emission and short half life (16.9 hr) makes 188Re an excellent isotope for radiotherapeutic applications. The similarity in the chemical behavior of Re and Tc means that imaging [protocols developed for 99mTc can be directly converted to therapeutic protocols for 188Re. Unfortunately the short half-life that makes Re attractive as a therapeutic agent makes it impossible to supply from a central source. Current generators are not adequate for the reliable delivery of pure 188Re at the end user site. The aim of this project is to develop a superior generator system for 188Re with an increased operating life to reduce the cost and improve the availability of the radioisotope to end-users. Crystalline inorganic compounds under consideration are layered aluminum mixed hydroxides, which can be synthesized as anion exchangers. The ideal compound strongly retains divalent tungstate (WO4 =) but not monovalent perrhenate (ReO4-). After testing a range of compositions for both magnesium and lithium aluminates compositions were entitled with high tungstate retentions (Kd >1.8 . 10[6] for Mg and >8 . 10[4] for Li). Based on equilibrium tests, these compositions had WO4=/ReO4 - separation factors of 18,000 and 500 respectively. The compositions were pelletized (<300 mu m) and used to produce small generators, which were tested and found to reliably deliver 188Re completely free of 188W, demonstrating separation factors greater than those seen in the equilibration tests. Phase II of this project will include improved pelletization and exchange kinetics for the ion exchangers and will culminate in the fabrication and testing of full size generators based on this technology. The ultimate goal of this project is a commercially viable 188Re generator for use in end use facilities such as hospitals, radiopharmacies, and regional radiopharmacies serving multiple hospitals. This will improve the availability of 188Re for use as the active component for radioimmunotherapy (RIT) and similar techniques.

描述（由申请人提供）： 高能 β (β-) 发射和短半衰期（16.9 小时）使 188Re 成为放射治疗应用的优异同位素。 Re 和 Tc 化学行为的相似性意味着为 99mTc 开发的成像方案可以直接转换为 188Re 的治疗方案。不幸的是，半衰期短使得 Re 作为一种治疗剂很有吸引力，但它不可能从中央来源供应。目前的发电机不足以在最终用户现场可靠地输送纯 188Re。该项目的目的是开发一种卓越的 188Re 发电机系统，延长其使用寿命，以降低成本并提高最终用户对放射性同位素的可用性。正在考虑的结晶无机化合物是层状铝混合氢氧化物，可以将其合成为阴离子交换剂。理想的化合物强烈保留二价钨酸盐 (WO4 =)，但不保留一价高铼酸盐 (ReO4-)。在测试了一系列铝酸镁和锂组合物后，组合物具有高钨酸盐保留率（镁的 Kd > 1.8 . 10[6]，锂的 Kd > 8. 10[4]）。基于平衡测试，这些组合物的WO4=/ReO4——分离因子分别为18,000和500。将组合物造粒（<300μm）并用于生产小型发生器，经过测试发现其能够可靠地输送完全不含 188W 的 188Re，证明分离因子大于平衡测试中所见的分离因子。该项目的第二阶段将包括改进离子交换器的造粒和交换动力学，并将最终基于该技术制造和测试全尺寸发生器。该项目的最终目标是商业上可行的 188Re 发生器，用于最终使用设施，例如医院、放射性药房和为多家医院服务的区域放射性药房。这将提高 188Re 作为放射免疫疗法 (RIT) 和类似技术的活性成分的可用性。